Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (71-80 of 242) with videos related to

Pageof 25
Sort By:
Cancer Science|January 28, 2021
Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 studyTakashi Seto, Kadoaki Ohashi, Shunichi Sugawara, et al.
Anticancer Research|June 10, 2010
Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapyKoji Yamazaki, Kenji Sugio, Takeharu Yamanaka, et al.
Surgery Today|June 14, 2015
Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancerTomoyoshi Takenaka, Eiko Inamasu, Tsukihisa Yoshida, et al.
Drugs - Real World Outcomes|September 12, 2021
Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims DatabasesRoss A Soo, Takashi Seto, Jhanelle E Gray, et al.
Oncotarget|May 29, 2018
Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring <i>ROS1</i> fusions: a phase I studyYutaka Fujiwara, Masayuki Takeda, Noboru Yamamoto, et al.
Japanese Journal of Clinical Oncology|November 15, 2017
Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancerTakashi Seto, Fumihiko Hirai, Hideo Saka, et al.
Japanese Journal of Clinical Oncology|March 16, 2016
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patientsAkira Inoue, Kazushi Yoshida, Satoshi Morita, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohortIsamu Okamoto, Satoshi Morita, Naoki Tashiro, et al.
Molecular and Clinical Oncology|April 14, 2016
<i>c-kit</i> mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case reportFumihiko Hirai, Makoto Edagawa, Shinichiro Shimamatsu, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 24, 2015
Influence of the distance between home and the hospital on patients with surgically resected non-small-cell lung cancerTomoyoshi Takenaka, Eiko Inamasu, Tsukihisa Yoshida, et al.
Pageof 25

Showing results (71-80 of 242) with videos related to

Sort By:
Pageof 25
Cancer Science|January 28, 2021
Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 studyTakashi Seto, Kadoaki Ohashi, Shunichi Sugawara, et al.
Anticancer Research|June 10, 2010
Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapyKoji Yamazaki, Kenji Sugio, Takeharu Yamanaka, et al.
Surgery Today|June 14, 2015
Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancerTomoyoshi Takenaka, Eiko Inamasu, Tsukihisa Yoshida, et al.
Drugs - Real World Outcomes|September 12, 2021
Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims DatabasesRoss A Soo, Takashi Seto, Jhanelle E Gray, et al.
Oncotarget|May 29, 2018
Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring <i>ROS1</i> fusions: a phase I studyYutaka Fujiwara, Masayuki Takeda, Noboru Yamamoto, et al.
Japanese Journal of Clinical Oncology|November 15, 2017
Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancerTakashi Seto, Fumihiko Hirai, Hideo Saka, et al.
Japanese Journal of Clinical Oncology|March 16, 2016
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patientsAkira Inoue, Kazushi Yoshida, Satoshi Morita, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohortIsamu Okamoto, Satoshi Morita, Naoki Tashiro, et al.
Molecular and Clinical Oncology|April 14, 2016
<i>c-kit</i> mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case reportFumihiko Hirai, Makoto Edagawa, Shinichiro Shimamatsu, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|July 24, 2015
Influence of the distance between home and the hospital on patients with surgically resected non-small-cell lung cancerTomoyoshi Takenaka, Eiko Inamasu, Tsukihisa Yoshida, et al.
Pageof 25